Relco Pharma Chem Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.50 M
as on 17-11-2024
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.40 Cr
as on 17-11-2024
- Satisfied Charges ₹ 7.50 M
as on 17-11-2024
- Revenue 81.06%
(FY 2023)
- Profit 55.31%
(FY 2023)
- Ebitda 134.56%
(FY 2023)
- Net Worth -89.96%
(FY 2023)
- Total Assets 1.07%
(FY 2023)
About Relco Pharma Chem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹2.40 Cr. The company has closed loans amounting to ₹7.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ravikumar Patel, Chirag Patel, Akash Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2019PTC109508
- Company No.
109508
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Relco Pharma Chem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chirag Patel  | Director | 23-Mar-2023 | Current |
| Ravikumar Patel | Director | 23-Mar-2023 | Current |
| Akash Patel | Director | 05-Sep-2022 | Current |
| Jay Patel | Director | 05-Sep-2022 | Current |
Financial Performance of Relco Pharma Chem.
Relco Pharma Chem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 81.06% increase. The company also saw a substantial improvement in profitability, with a 55.31% increase in profit. The company's net worth observed a substantial decline by a decrease of 89.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Relco Pharma Chem?
In 2023, Relco Pharma Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Oryn Healthcare LlpActive 5 years 8 monthsRavikumar Patel, Chirag Patel and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Jul 2023 | ₹2.40 Cr | Open |
Others Creation Date: 27 Jan 2021 | ₹7.50 M | Satisfied |
How Many Employees Work at Relco Pharma Chem?
Unlock and access historical data on people associated with Relco Pharma Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Relco Pharma Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Relco Pharma Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
